Content area
Full text
Received May 30, 2017; Revised Jul 20, 2017; Accepted Aug 1, 2017
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Asthma is a chronic inflammatory disease of the airways. Approximately 5%–10% of patients with asthma exhibit severe symptoms that are not easily controlled by regular medication [1–3]. Severe neutrophilic asthma is a major phenotype of severe asthma (SA), in which neutrophils significantly contribute to the exacerbation of symptoms and airway remodeling [4]. However, the role of neutrophils in pathophysiological mechanisms responsible for SA has not been fully determined.
Recent studies have demonstrated that neutrophils participate in autoimmune disease [5, 6]; furthermore, autoimmune mechanisms, such as the deposition of autoantibodies in specific tissues, are known to play a role in asthma [7]. Our group previously found circulating autoantibodies, such as anti-cytokeratin (CK) 18, anti-CK19, and anti-
Neutrophils, which are the most abundant leukocytes in humans, produce cytotoxic granule proteins [12]. Recently, it has been suggested that activated neutrophils undergo a novel form of cell death during which a meshwork of chromatin with bound granule proteins, known as neutrophil extracellular DNA traps (NETs), is released [13, 14]. A previous study demonstrated high...